Business
AXIM® Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing
AXIM® Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n Leading Diagnostic Healthcare Company Announces Provisional Patent Filing on Proprietary Use of Materials for Ophthalmological Test Strip Manufacturing SAN DIEGO, CA, March 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today the filing of a provisional patent application with the U.S. Patent and Trademark Office (US PTO) for the innovative use of proprietary materials in its ocular diagnostic assays that significantly increases sample disbursement. This development increases efficacy and accuracy of diagnostic test readings as well as usability for clinicians. AXIM's diagnostic assays are unique in that they require a significantly reduced tear sample from patients, greatly increasing the ease of collection at the point-of-care from clinicians. Where most commercially available tests require a tear sample size up to ~10 microliters, AXIM's solutions measure biomarker levels with just 1 microliter. Given the smaller sample size requirements, existing mechanisms for sample disbursement proved less than optimal. As such, AXIM’s research and development team has developed a new and proprietary methodology for tear sample disbursement within a given assay, which is showing considerable evidence of increased sensitivity, specificity and accuracy of measurement readings as well as useability. Legacy materials have shown evidence of inconsistent disbursement of the tear sample in test areas, creating lower accuracy test results given a smaller sample size. AXIM's new methodology ensures unparalleled consistency in tear sample disbursement and a color indication shows the correct application of the sample into the assay by clinicians. This application greatly increases the accuracy of administered tests and useability by clinicians. \"This innovation is yet another step in the execution of a long-planned, go-to-market strategy for AXIM's diagnostic solutions,” said John Huemoeller II, CEO of AXIM Biotechnologies. “Being able to combine a very small tear sample from patients with optimized test accuracy results has created an overall platform that is truly a step above the rest and a significant advancement in terms of...